- Home
- PCQ vs DVAX Comparison
PCQ vs DVAX Comparison
Compare PCQ & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCQ
- DVAX
- Stock Information
- Founded
- PCQ 2001
- DVAX 1996
- Country
- PCQ United States
- DVAX United States
- Employees
- PCQ N/A
- DVAX N/A
- Industry
- PCQ Investment Managers
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- PCQ Finance
- DVAX Health Care
- Exchange
- PCQ Nasdaq
- DVAX Nasdaq
- Market Cap
- PCQ 163.2M
- DVAX 1.3B
- IPO Year
- PCQ N/A
- DVAX 2004
- Fundamental
- Price
- PCQ $8.78
- DVAX $9.53
- Analyst Decision
- PCQ
- DVAX Buy
- Analyst Count
- PCQ 0
- DVAX 4
- Target Price
- PCQ N/A
- DVAX $26.50
- AVG Volume (30 Days)
- PCQ 69.6K
- DVAX 1.9M
- Earning Date
- PCQ 01-01-0001
- DVAX 11-06-2025
- Dividend Yield
- PCQ 4.63%
- DVAX N/A
- EPS Growth
- PCQ N/A
- DVAX N/A
- EPS
- PCQ N/A
- DVAX N/A
- Revenue
- PCQ N/A
- DVAX $316,268,000.00
- Revenue This Year
- PCQ N/A
- DVAX $23.23
- Revenue Next Year
- PCQ N/A
- DVAX $16.57
- P/E Ratio
- PCQ N/A
- DVAX N/A
- Revenue Growth
- PCQ N/A
- DVAX 26.66
- 52 Week Low
- PCQ $8.19
- DVAX $9.20
- 52 Week High
- PCQ $10.50
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- PCQ 85.56
- DVAX 40.00
- Support Level
- PCQ $8.60
- DVAX $9.20
- Resistance Level
- PCQ $8.70
- DVAX $9.94
- Average True Range (ATR)
- PCQ 0.07
- DVAX 0.30
- MACD
- PCQ 0.05
- DVAX -0.04
- Stochastic Oscillator
- PCQ 96.49
- DVAX 34.91
About PCQ PIMCO California Municipal Income Fund
PIMCO California Municipal Income Fund is a closed-end management investment company. It seeks to provide current income exempt from federal and California income tax. The fund makes investments in different sectors such as healthcare, property, education, Natural Gas, and others.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.